Nonmetastatic renal-cell carcinoma: is it really possible to define rational guidelines for post-treatment follow-up?
Defining rational follow-up guidelines in patients treated for cancer is important, from both a medical and an economical perspective. Renal-cell carcinoma is reputed to be unpredictable in its course and only a few, and often contradictory, follow-up guidelines exist for patients treated for nonmetastatic renal-cell carcinoma. Recent advances in tumor biology have contributed to a better understanding of this cancer and have indicated that personalized follow-up regimens, based on tumor and host molecular characteristics, might be possible in the near future.
Rouvière
Olivier
O
Department of Urinary, Vascular and Interventional Radiology, Edouard Herriot Hospital, Lyon, France. olivier.rouviere@netcourrier.com
Bouvier
Raymonde
R
Négrier
Sylvie
S
Badet
Lionel
L
Lyonnet
Denis
D
D014408:Biomarkers, Tumor / Q000096:biosynthesis / Q000235:genetics; D002292:Carcinoma, Renal Cell / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D005500:Follow-Up Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D009364:Neoplasm Recurrence, Local / Q000473:pathology*; D009367:Neoplasm Staging; D017410:Practice Guidelines as Topic; D011379:Prognosis
D014408:Biomarkers, Tumor